title: Interstitial iridium-192 for bladder cancer (a multicentric survey: 205 patients).
abstract: Interstitial irradiation is a technique currently used in the treatment of bladder cancer. We report the data on 205 patients (177 men and 28 women) treated in eight French centers. The patients had received the following treatment: a short course of pre-operative pelvic irradiation, followed by surgery consisting of partial cystectomy or tumor resection, and implantation of plastic tubes filled with inactive lead wires, which were replaced by iridium 192 wires. The tumor characteristics were: transitional cell carcinoma, 88.8%; mean size of the tumor, 29 mm; pathological stages: pTis, 1; pT1, 98; pT2, 66; pT3a, 26; pT3b, 9; pT4, 1; unknown, 4 respectively; surgical lymph node status: N+, 3; N-, 118; no node dissection, 84. The mean follow-up was 51 months. Intravesical failures were seen in 35 patients (17.0%), 25 (71.4%) of them without metastases or regional recurrences. Twenty-one patients (10.2%) presented distant metastases, 2/3 of them suffered no bladder relapse. The 5-year survival, calculated according to the Kaplan-Meier method (all causes of death taken together) was 77.4% for the T1, 62.9% for the T2, and 46.8% for the T3. Fifty-three patients had immediate side-effects and three died from surgical complications. Twenty-nine patients had delayed bladder side-effects (haematuria, fistula, chronic cystitis). Six patients presented an ureteral stenosis. Of the disease-free survivors, 96.1% retained the bladder function. Three factors were significantly predictive of delayed side-effects: partial cystectomy, pre-operative radiotherapy total dose, and linear activity of the wires (p < 0.01). Comparing our results to different authors' series interstitial irradiation is likely to provide a high local and general control of the disease and good quality of life in patients with selected tumors.
authors.affiliation: Centre Jean Perrin, Département de Radiothérapie, Clermont-Ferrand, France.
authors.forename: R
authors.initials: R
authors.lastname: Rozan
authors.forename: E
authors.initials: E
authors.lastname: Albuisson
authors.forename: D
authors.initials: D
authors.lastname: Donnarieix
authors.forename: B
authors.initials: B
authors.lastname: Giraud
authors.forename: J J
authors.initials: JJ
authors.lastname: Mazeron
authors.forename: J P
authors.initials: JP
authors.lastname: Gerard
authors.forename: M
authors.initials: M
authors.lastname: Pernot
authors.forename: A
authors.initials: A
authors.lastname: Gerbaulet
authors.forename: F
authors.initials: F
authors.lastname: Baillet
authors.forename: J
authors.initials: J
authors.lastname: Douchez
mesh_terms: D000230:Adenocarcinoma / Q000453:epidemiology / Q000532:radiotherapy* / Q000601:surgery; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001918:Brachytherapy; D002294:Carcinoma, Squamous Cell / Q000453:epidemiology / Q000532:radiotherapy* / Q000601:surgery; D002295:Carcinoma, Transitional Cell / Q000453:epidemiology / Q000532:radiotherapy* / Q000601:surgery; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D005602:France / Q000453:epidemiology; D006801:Humans; D007496:Iridium Radioisotopes / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology; D012189:Retrospective Studies; D015996:Survival Rate; D001749:Urinary Bladder Neoplasms / Q000453:epidemiology / Q000532:radiotherapy* / Q000601:surgery
chemical_list: D007496:Iridium Radioisotopes